Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06730512 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-06730512 | EXPERIMENTAL | Study Drug being used in the study |
| Placebo | PLACEBO_COMPARATOR | Placebo for IV/SC administration |
| Name | Type | Description |
|---|---|---|
| PF-06730512 | BIOLOGICAL | Comparison of different dosages of PF-06730512 to Placebo |
| Placebo | DRUG | Comparison of Placebo to different doses of PF-06730512 |
Inclusion Criteria: * Healthy female subjects of nonchildbearing potential and/or male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical exami...
PF-06730512 is an investigational monoclonal antibody developed by Pfizer. It has been studied in a Phase 1 clinical trial evaluating its safety, tolerability, and pharmacokinetics in healthy adult volunteers. The specific disease indications for which it is being developed have not been publicly disclosed.
PF-06730512 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. Pfizer sponsored the Phase 1 clinical trial of the compound conducted in Belgium.
PF-06730512 is in Phase 1 clinical development. It is an investigational monoclonal antibody and has not been approved by the FDA. The single Phase 1 trial evaluating the drug has been completed.
PF-06730512 has been evaluated in one clinical trial, NCT03146065, titled Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of PF-06730512. The Phase 1 trial enrolled 79 healthy adult volunteers in Belgium and has been completed.
The Phase 1 trial NCT03146065 was a randomized, double-blind, placebo-controlled study of single and multiple doses of PF-06730512. It enrolled 79 healthy volunteers of all sexes, aged 18 years and older, in Belgium, and evaluated safety, tolerability, and pharmacokinetics.